Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities-Reference-Cited by-同舟云学术

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities

Published:2020-08-27 Issue:12 Volume:28 Page:6175-6181
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Cooksley Tim,Girotra Monica,Ginex Pamela,Gordon Ruth Ann,Anderson Ronald,Blidner Ada,Choi Jennifer,Dougan Michael,Glezerman Ilya,Gupta Dipti,Johnson Douglas,Shannon Vickie R.,Suarez-Almazor Maria,Rapoport Bernardo L.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-020-05709-1.pdf

Reference31 articles.

1. Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, Callahan MK, Atkins MB, Sharon E, Antonia SJ, West P, Gravell AE; Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration (2018) The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr 2(3): 21. doi: https://doi.org/10.1093/jncics/pky021.

2. Higham C, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, Lorigan P, Morganstein D, Trainer PJ, Society for Endocrinology Clinical Committee (2018) Society for Endocrinology Endocrine Emergency Guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7(7):G1–G7. https://doi.org/10.1530/EC-18-0068

3. Ryder M, Callahan M, Postow M, Wolchok J, Fagin JA (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21(2):371–381. https://doi.org/10.1530/ERC-13-0499

4. Joshi MN, Whitelaw BC, Carroll PV (2018) Mechanisms in endocrinology: hypophysitis: diagnosis and treatment. Eur J Endocrinol 179(3):R151–R163. https://doi.org/10.1530/EJE-17-0009

5. Webb P, Rice TW, Cooksley T (2017) Problem-based review: immune-mediated complications of “checkpoint inhibitors” for the acute physician. Acute Med 16(1):21–24

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From cortisol-producing adrenal adenoma to atrial myxoma, through nivolumab-induced hypophysitis: a complicated case report of Carney Complex;Endocrine;2024-09-01

2. Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study;Immunotherapy;2024-06-18

3. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis;BMC Cancer;2024-04-17

4. Immune checkpoint inhibitors and risk of immune-mediated adverse events: a cohort study comparing extended versus standard interval administration;Clinical and Experimental Medicine;2024-02-22

5. Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist;Current Dermatology Reports;2023-11-30